Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells

Revital Shamri; Gerald Dubois; Veit J. Erpenbeck; David Mankuta; David A. Sandham; Francesca Levi-Schaffer

doi:10.1111/cea.13304

Fevipiprant, a DP₂ receptor antagonist, inhibits eosinophil migration towards mast cells

Revital Shamri, Gerald Dubois, Veit J. Erpenbeck, David Mankuta, David A. Sandham, Francesca Levi-Schaffer^*

^*Corresponding author for this work

School of Pharmacy

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	255-257
Number of pages	3
Journal	Clinical and Experimental Allergy
Volume	49
Issue number	2
DOIs	https://doi.org/10.1111/cea.13304
State	Published - Feb 2019

Bibliographical note

Funding Information:
We are grateful to Helena Migalovich, Ludovica Arpinati and Man-sour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

Funding Information:
We are grateful to Helena Migalovich, Ludovica Arpinati and Mansour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

Access to Document

10.1111/cea.13304

Cite this

@article{09fc7b9a5ea24edd87b5fac2b16ef26f,

title = "Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells",

author = "Revital Shamri and Gerald Dubois and Erpenbeck, {Veit J.} and David Mankuta and Sandham, {David A.} and Francesca Levi-Schaffer",

note = "Funding Information: We are grateful to Helena Migalovich, Ludovica Arpinati and Man-sour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland. Funding Information: We are grateful to Helena Migalovich, Ludovica Arpinati and Mansour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland.",

year = "2019",

month = feb,

doi = "10.1111/cea.13304",

language = "אנגלית",

volume = "49",

pages = "255--257",

journal = "Clinical and Experimental Allergy",

issn = "0954-7894",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells

AU - Shamri, Revital

AU - Dubois, Gerald

AU - Erpenbeck, Veit J.

AU - Mankuta, David

AU - Sandham, David A.

AU - Levi-Schaffer, Francesca

N1 - Funding Information: We are grateful to Helena Migalovich, Ludovica Arpinati and Man-sour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland. Funding Information: We are grateful to Helena Migalovich, Ludovica Arpinati and Mansour Seaf who contributed to different aspects to this research effort in the past. This study was sponsored by Novartis Pharma AG, Basel, Switzerland.

PY - 2019/2

Y1 - 2019/2

UR - http://www.scopus.com/inward/record.url?scp=85057253626&partnerID=8YFLogxK

U2 - 10.1111/cea.13304

DO - 10.1111/cea.13304

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 30379368

AN - SCOPUS:85057253626

SN - 0954-7894

VL - 49

SP - 255

EP - 257

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

IS - 2

ER -

Fevipiprant, a DP2 receptor antagonist, inhibits eosinophil migration towards mast cells

Bibliographical note

Access to Document

Other files and links

Cite this

Fevipiprant, a DP₂ receptor antagonist, inhibits eosinophil migration towards mast cells